
Celebrating 30 years of the MIDSPAN Studies







Haemostasis and thrombosis in the MIDSPAN study Gordon Lowe






LOW CLOTTING FACTORS INCREASE BLEEDING, BUT DECREASE THROMBOSIS

| e.g. haemophilia (x-linked recessive) | | |
|-------------------------------------------|-------|----------|
| | Level | CHD risk |
| Normal | 100% | 1 |
| Carrier female | 50% | 0.7 |
| Haemophilia male | <20% | 0.2 |
| (Rosendaal et al 1991; Sramek et al 2003) | | |







LOW COAGULATION INHIBITION (FACTOR V LEIDEN) AND THROMBOSIS


- Genetic cause (Bertina et al, 1994) of resistance to activated protein C (natural anticoagulant, Dahlback et al 1993); 3% of population (Lowe et al, 1999,2001)
- Venous thrombosis 5.0 (Rosendaal et al,1995)
 CHD 1.25 (Ye et al, 2005)

COAGULATION ACTIVATION (D-DIMER)

- Heritability 70% (Ariens et al, 2002; Banfield et al, 2005)
- Venous thrombosis 1.7 (Lowe et al, 1999; Prandoni et al, 2004)
- CHD 1.7 (Lowe et al, 1998)







D-DIMER AND CHD

Thrombosis Prevention Trial showed that

low dose Warfarin lowers risk of CHD, if

lowers D-dimer (McCallum et al, 2004)

MIDSPAN AND HAEMOSTASIS

- Heritability
- CHD risk factors
- COC and HRT 3 X DVT
 - 1.5 x stroke, CHD
 - mechanisms?

ORAL OESTROGENS AND COAGULATION

- ↑ factor IX
- 🗸 antithrombin
- ↑ resistance to APC (like V Leiden)
- [†] D-dimer
- ↑ CRP
- All associated with DVT, especially in HRT users (Lowe et al, 1999)

MIDSPAN STUDIES OF FEMALE HORMONES AND COAGULATION

- No effect of transdermal HRT, cf. oral HRT (Lowe et al, 2001)
- No effect of progesterone–only OCP, cf. COC (Rumley et al, 2003)
- Consistent with no DVT risk in epidemiological studies (Scarabin et al, 2003)
- Consider in women at increased thrombotic risk

CONCLUSIONS

- Haemostatic factors are associated with increased risk of arterial and venous thrombosis in epidemiological studies
- May be biological basis for associations
- May predict high risk groups for selection of therapies (e.g. oral contraceptives and HRT) or antithrombotic therapies